Skip to main content
SpringerLink
Log in

Gastric Cancer: Locoregional Disease

General Section. Locoregional Disease

  • Chapter
  • First Online:
Practical Medical Oncology Textbook

Part of the book series: UNIPA Springer Series ((USS))

  • 3347 Accesses

Abstract

Gastric cancer (GC) is still a worldwide major leading cause of cancer death which shows large geographical differences. Despite an overall decline in incidence and mortality over the last decades, GC remains a poor prognosis disease since patients often present with advanced stage of disease. A large number of risk factors have been associated with GC. Thus, prevention (environment and lifestyle factors) and early diagnosis may be the most promising strategies for cancer control and key strategies to reduce mortality. Surgical resection remains the main form of curative treatment whenever feasible. Endoscopic approaches have been used as valid alternatives to surgery for selected patients. Unlike the extent of resection of the primary tumor, lymph node resection has been considered the most important surgical prognostic factor. A multimodality approach, including perioperative chemotherapy or chemoradiation, has been suggested as the standard treatment for locally advanced GCs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666–73.

    Article  CAS  PubMed  Google Scholar 

  3. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer. 2001;84:400–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  5. Norouzinia M, Asadzadeh H, Shalmani HM, Al Dulaimi D, Zali MR. Clinical and histological indicators of proximal and distal gastric cancer in eight provinces of Iran. Asian Pac J Cancer Prev. 2012;13:5677–9.

    Article  CAS  PubMed  Google Scholar 

  6. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at A HISTO-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    Article  CAS  PubMed  Google Scholar 

  7. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.

    CAS  PubMed  Google Scholar 

  8. Carcas LP. Gastric cancer review. J Carcinog. 2014;13:14.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23:700–13.

    Article  Google Scholar 

  10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  11. Stock M, Otto F. Gene deregulation in gastric cancer. Gene. 2005;360:1–19.

    Article  CAS  PubMed  Google Scholar 

  12. Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc. 2014;47:478–89.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yu X, Hu F, Li C, Yao Q, Zhang H, Xue Y. Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer. Onco Targets Ther. 2018;11:1037–44.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect. 2009;15:971–6.

    Article  CAS  PubMed  Google Scholar 

  15. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst. 1991;83:640–3.

    Article  CAS  PubMed  Google Scholar 

  18. Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019;30:781–7.

    Article  CAS  PubMed  Google Scholar 

  19. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.

    Article  CAS  PubMed  Google Scholar 

  20. Kim Y, Park J, Nam BH, Ki M. Stomach cancer incidence rates among Americans, Asian Americans and Native Asians from 1988 to 2011. Epidemiol Health. 2015;37:e2015006.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kamineni A, Williams MA, Schwartz SM, Cook LS, Weiss NS. The incidence of gastric carcinoma in Asian migrants to the United States and their descendants. Cancer Causes Control. 1999;10:77–83.

    Article  CAS  PubMed  Google Scholar 

  22. Buckland G, Travier N, Huerta JM, et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer. 2015;137:598–606.

    Article  CAS  PubMed  Google Scholar 

  23. Lin SH, Li YH, Leung K, Huang CY, Wang XR. Salt processed food and gastric cancer in a Chinese population. Asian Pac J Cancer Prev. 2014;15:5293–8.

    Article  PubMed  Google Scholar 

  24. Massarrat S, Stolte M. Development of gastric cancer and its prevention. Arch Iran Med. 2014;17:514–20.

    PubMed  Google Scholar 

  25. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67:253–6.

    Article  PubMed  Google Scholar 

  26. Nishino Y, Inoue M, Tsuji I, et al. Tobacco smoking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2006;36:800–7.

    Article  PubMed  Google Scholar 

  27. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2008;19:689–701.

    Article  PubMed  Google Scholar 

  28. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–86.

    Article  CAS  PubMed  Google Scholar 

  29. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses. 2012;4:3420–39.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–49.

    Article  CAS  PubMed  Google Scholar 

  31. Choi YJ, Kim N. Gastric cancer and family history. Korean J Intern Med. 2016;31:1042–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Choi YJ, Kim N, Jang W, et al. Familial clustering of gastric cancer: a retrospective study based on the number of first-degree relatives. Medicine (Baltimore). 2016;95:e3606.

    Article  PubMed  Google Scholar 

  33. Yamaguchi S, Sakata Y, Iwakiri R, et al. Increase in endoscopic and laparoscopic surgery regarding the therapeutic approach of gastric cancer detected by cancer screening in Saga Prefecture, Japan. Intern Med. 2016;55:1247–53.

    Article  PubMed  Google Scholar 

  34. Syrjänen K, Eskelinen M, Peetsalu A, et al. GastroPanel® biomarker assay: the most comprehensive test for. Anticancer Res. 2019;39:1091–104.

    Article  PubMed  Google Scholar 

  35. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133:659–72.

    Article  CAS  PubMed  Google Scholar 

  36. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205–23.

    Article  PubMed  Google Scholar 

  37. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.

    Article  CAS  PubMed  Google Scholar 

  38. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, et al. Precancerous conditions after H. pylori eradication: a randomized double blind study in first degree relatives of gastric cancer patients. Arch Iran Med. 2012;15:664–9.

    PubMed  Google Scholar 

  40. Valenzuela MA, Canales J, Corvalán AH, Quest AF. Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis. World J Gastroenterol. 2015;21:12742–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:403–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Valenzuela M, Bravo D, Canales J, et al. Helicobacter pylori-induced loss of survivin and gastric cell viability is attributable to secreted bacterial gamma-glutamyl transpeptidase activity. J Infect Dis. 2013;208:1131–41.

    Article  CAS  PubMed  Google Scholar 

  43. Varon C, Dubus P, Mazurier F, et al. Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology. 2012;142:281–91.

    Article  PubMed  Google Scholar 

  44. Forman D. Re: the role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:1013–1014; author reply 1014.

    Article  PubMed  Google Scholar 

  45. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455; quiz 1456.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23–32.

    Article  PubMed  Google Scholar 

  47. Hwang J, Min BH, Jang J, et al. MicroRNA expression profiles in gastric carcinogenesis. Sci Rep. 2018;8:14393.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Libânio D, Dinis-Ribeiro M, Pimentel-Nunes P. Helicobacter pylori and microRNAs: relation with innate immunity and progression of preneoplastic conditions. World J Clin Oncol. 2015;6:111–32.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol. 2008;14:1149–55.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.

    Article  CAS  PubMed  Google Scholar 

  51. Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol. 2014;20:5679–84.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Murakami T. Early cancer of the stomach. World J Surg. 1979;3:685–92.

    Article  CAS  PubMed  Google Scholar 

  53. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3–43.

    Google Scholar 

  54. Li C, Oh SJ, Kim S, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77:197–204.

    Article  PubMed  Google Scholar 

  55. Fléjou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27–31.

    Article  PubMed  Google Scholar 

  56. Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14:1853–9.

    Article  PubMed  Google Scholar 

  57. Bhutani MS, Hawes RH, Hoffman BJ. A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion. Gastrointest Endosc. 1997;45:474–9.

    Article  CAS  PubMed  Google Scholar 

  58. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12:6–22.

    Article  CAS  PubMed  Google Scholar 

  59. Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. Radiology. 2007;242:472–82.

    Article  PubMed  Google Scholar 

  60. Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S38–47.

    Article  PubMed  Google Scholar 

  61. Stein HJ, Feith M, Siewert JR. Cancer of the esophagogastric junction. Surg Oncol. 2000;9:35–41.

    Article  CAS  PubMed  Google Scholar 

  62. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–30.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20:217–25.

    Article  PubMed  Google Scholar 

  64. Huang Q, Shi J, Feng A, et al. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol. 2011;24:138–46.

    Article  PubMed  Google Scholar 

  65. Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014;16:e1.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Nordgård O, Tjensvoll K, Gilje B, Søreide K. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. Br J Surg. 2018;105:e110–20.

    Article  PubMed  Google Scholar 

  67. Wang H, Li B, Liu Z, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92–100.

    Article  CAS  PubMed  Google Scholar 

  68. Network CGAR. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

    Article  Google Scholar 

  69. Kankeu Fonkoua L, Yee NS. Molecular characterization of gastric carcinoma: therapeutic implications for biomarkers and targets. Biomedicine. 2018;6:32.

    Google Scholar 

  70. Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123–33.

    Article  PubMed  Google Scholar 

  71. Nishikawa J, Iizasa H, Yoshiyama H, et al. The role of epigenetic regulation in Epstein-Barr virus-associated gastric cancer. Int J Mol Sci. 2017;18:1606.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Li B, Nie Z, Zhang D, et al. Roles of circulating endothelial progenitor cells and endothelial cells in gastric carcinoma. Oncol Lett. 2018;15:324–30.

    PubMed  Google Scholar 

  73. Ishiguro H, Kimura M, Takeyama H. Role of microRNAs in gastric cancer. World J Gastroenterol. 2014;20:5694–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Puneet KHR, Kumari S, Tiwari S, Khanna A, Narayan G. Epigenetic mechanisms and events in gastric cancer-emerging novel biomarkers. Pathol Oncol Res. 2018;24:757.

    Article  CAS  PubMed  Google Scholar 

  75. Mirabella AC, Foster BM, Bartke T. Chromatin deregulation in disease. Chromosoma. 2016;125:75–93.

    Article  CAS  PubMed  Google Scholar 

  76. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Verma R, Sharma PC. Next generation sequencing-based emerging trends in molecular biology of gastric cancer. Am J Cancer Res. 2018;8:207–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Tegels JJ, De Maat MF, Hulsewé KW, Hoofwijk AG, Stoot JH. Improving the outcomes in gastric cancer surgery. World J Gastroenterol. 2014;20:13692–704.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2015;47:829–54.

    Article  PubMed  Google Scholar 

  80. Zhao Y, Wang C. Long-term clinical efficacy and perioperative safety of endoscopic submucosal dissection versus endoscopic mucosal resection for early gastric cancer: an updated meta-analysis. Biomed Res Int. 2018;2018:3152346.

    PubMed  PubMed Central  Google Scholar 

  81. Bösing NM, Goretzki PE, Röher HD. Gastric cancer: which patients benefit from systematic lymphadenectomy? Eur J Surg Oncol. 2000;26:498–505.

    Article  PubMed  Google Scholar 

  82. Kubota T, Hiki N, Sano T, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8.

    Article  PubMed  Google Scholar 

  83. Bozzetti F, Marubini E, Bonfanti G, et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 1997;226:613–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999;230:170–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ji X, Yan Y, Bu ZD, et al. The optimal extent of gastrectomy for middle-third gastric cancer: distal subtotal gastrectomy is superior to total gastrectomy in short-term effect without sacrificing long-term survival. BMC Cancer. 2017;17:345.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347:995–9.

    Article  CAS  PubMed  Google Scholar 

  87. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130:612–617; discussion 617-619.

    Article  CAS  PubMed  Google Scholar 

  88. Viñuela EF, Gonen M, Brennan MF, Coit DG, Strong VE. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg. 2012;255:446–56.

    Article  PubMed  Google Scholar 

  89. Kelly KJ, Selby L, Chou JF, et al. Laparoscopic versus open gastrectomy for gastric adenocarcinoma in the west: a case-control study. Ann Surg Oncol. 2015;22:3590–6.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Chen K, Pan Y, Zhang B, Maher H, Wang XF, Cai XJ. Robotic versus laparoscopic gastrectomy for gastric cancer: a systematic review and updated meta-analysis. BMC Surg. 2017;17:93.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Spanknebel KA, Brennan MF. Is D2 lymphadenectomy for gastric cancer a staging tool or a therapeutic intervention? Surg Oncol Clin N Am. 2002;11:415–430, xii.

    Article  PubMed  Google Scholar 

  92. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000;232:362–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1:125–33.

    Article  PubMed  Google Scholar 

  94. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11:1384–1393; discussion 1393-1384.

    Article  PubMed  Google Scholar 

  95. Biondi A, D'Ugo D, Cananzi FC, et al. Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer? Eur J Surg Oncol. 2015;41:779–86.

    Article  CAS  PubMed  Google Scholar 

  96. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. clinical classification. Jpn J Surg. 1981;11:127–39.

    Article  CAS  PubMed  Google Scholar 

  97. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with Para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.

    Article  CAS  PubMed  Google Scholar 

  98. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.

    Article  CAS  PubMed  Google Scholar 

  99. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.

    CAS  PubMed  Google Scholar 

  101. Mocellin S, Nitti D. Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials. Cancer Treat Rev. 2015;41:448–54.

    Article  PubMed  Google Scholar 

  102. Jatzko GR, Lisborg PH, Denk H, Klimpfinger M, Stettner HM. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer. 1995;76:1302–12.

    Article  CAS  PubMed  Google Scholar 

  103. Paul TO, Hoyt WF. Funduscopic appearance of papilledema with optic tract atrophy. Arch Ophthalmol. 1976;94:467–8.

    Article  PubMed  Google Scholar 

  104. Sierra A, Regueira FM, Hernández-Lizoáin JL, Pardo F, Martínez-Gonzalez MA, A-Cienfuegos J. Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. Ann Surg Oncol. 2003;10:219–26.

    Article  PubMed  Google Scholar 

  105. Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009;45:931–91.

    Article  PubMed  Google Scholar 

  107. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  108. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.

    Article  CAS  PubMed  Google Scholar 

  109. Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2010;362:858–9.

    Article  CAS  PubMed  Google Scholar 

  110. Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.

    Article  CAS  PubMed  Google Scholar 

  112. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–49.

    Article  CAS  PubMed  Google Scholar 

  113. Ajani JA, Buyse M, Lichinitser M, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the first-line advanced gastric cancer study. Eur J Cancer. 2013;49:3616–24.

    Article  CAS  PubMed  Google Scholar 

  114. Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24:2252–8.

    Article  PubMed  Google Scholar 

  115. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    Article  CAS  PubMed  Google Scholar 

  116. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430–6.

    Article  PubMed  Google Scholar 

  117. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.

    Article  CAS  PubMed  Google Scholar 

  118. Wang MJ, Li C, Sun Y, Shen FJ, Wang CB. Prognostic effect of adjuvant chemoradiotherapy for patients with gastric cancer: an updated evidence of randomized controlled trials. Oncotarget. 2017;8:102880–7.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388–98.

    Article  PubMed  Google Scholar 

  121. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 2007;18:1354–8.

    Article  PubMed  Google Scholar 

  122. Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16:1488–97.

    Article  PubMed  Google Scholar 

  123. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354:273–7.

    Article  CAS  PubMed  Google Scholar 

  124. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  PubMed  Google Scholar 

  125. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

    Article  CAS  PubMed  Google Scholar 

  126. Lee CK, Jung M, Kim HS, et al. S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial. Cancer Res Treat. 2018;51:1.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.

    Article  CAS  PubMed  Google Scholar 

  128. Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Barchi LC, Yagi OK, Jacob CE, et al. Predicting recurrence after curative resection for gastric cancer: external validation of the Italian Research Group for Gastric Cancer (GIRCG) prognostic scoring system. Eur J Surg Oncol. 2016;42:123–31.

    Article  CAS  PubMed  Google Scholar 

  130. Aurello P, Petrucciani N, Antolino L, Giulitti D, D'Angelo F, Ramacciato G. Follow-up after curative resection for gastric cancer: is it time to tailor it? World J Gastroenterol. 2017;23:3379–87.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Xue HG, Yang AH, Sun XG, Lu YY, Tian ZB. Expression of microRNA-328 functions as a biomarker for recurrence of Early Gastric Cancer (EGC) after endoscopic submucosal dissection (ESD) by modulating CD44. Med Sci Monit. 2016;22:4779–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Li Y, Liang J, Hou P. Hypermethylation in gastric cancer. Clin Chim Acta. 2015;448:124–32.

    Article  CAS  PubMed  Google Scholar 

  133. Tenderenda M. A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res. 2005;24:405–14.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Valerio Gristina and Nadia Barraco should be considered equally co-first authors.

Authors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Daniele Fanale & Antonio Russo

  2. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Valerio Gristina

  3. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Galvano

  4. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Nadia Barraco

  5. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  6. Universidad Ricardo Palma Instituto de Investigación en Ciencias Biomedicas, Lima, Peru

    Jhony Alberto De La Cruz Vargas

  7. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Maria La Mantia

  8. Medical-oncologist, University Hospital Antwerp, Edegem, Belgium

    Albert J. ten Tije

Authors
  1. Valerio Gristina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadia Barraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Galvano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniele Fanale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria La Mantia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc Peeters
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Albert J. ten Tije
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jhony Alberto De La Cruz Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Russo .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Russo

  2. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  3. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, NY, USA

    Christian Rolfo

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gristina, V. et al. (2021). Gastric Cancer: Locoregional Disease. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56051-5_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56050-8

  • Online ISBN: 978-3-030-56051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation